Clinical Trial Update: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing eribulin mesylate to paclitaxel as first- or second-line therapy for recurrent stage IIIC-IV breast cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Halaven (eribulin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Breast Adenocarcinoma, HER2/Neu Negative | Phase 3 | Status: SUSPENDED | Results posted: 2023-09-06